NHS given go-ahead to prescribe new drug which eases agony of rheumatoid arthritis
A drug that could ease the agony of thousands of rheumatoid arthritis sufferers has been given the go-ahead for many more NHS patients in England and Wales.
RoActemra, which is the first innovation in the field for ten years, is being recommended for patients who have failed on standard treatments.
It is the first time RoActemra has been approved for NHS patients in England and Wales with moderate to severe rheumatoid arthritis who are at an early stage in the disease.
Hope: The NHS given go-ahead to prescribe RoActemra which eases the agony of rheumatoid arthritis
The drug has been available for early use in Scotland for two years.
At present in England and Wales it is used by only 1,200 patients at later stages of the disease. The decision by the Government’s rationing body, the National Institute for Health and Clinical Excellence (Nice), means up to 40,000 more patients will be eligible.
The 9,000 annual cost of RoActemra, also known as tocilizumab, is the same as other advanced ‘biologic’ drugs already being used, but a discount scheme has been agreed with manufacturers Roche.
Trial data shows almost half of patients on RoActemra are in remission – with virtually no symptoms – after a year compared with 8 per cent on a commonly used drug called methotrexate.
The rate of remission is almost six times higher than on methotrexate alone.
Trial data shows almost half of patients on RoActemra are in remission with virtually no symptoms
The new drug is a laboratory-manufactured antibody that blocks the activity of interleukin 6 (IL-6), an important immune system signalling molecule that underpins many inflammatory processes.
Because RoActemra works in a completely different way to existing drugs it is likely to be effective in some patients where the other drugs don’t work or have stopped working.
John Isaacs, professor of clinical rheumatology at Newcastle University, says it vital sufferers have options
John Isaacs, professor of clinical rheumatology at Newcastle University, said: ‘Rheumatoid arthritis is an unrelenting disease and it is vital that patients have options available to them when they are no longer responding to, or can no longer tolerate, their current treatment.’
The disease occurs when the body’s immune system attacks the joints causing pain and swelling, most commonly in the hands, wrists and feet.
NHS figures suggest it affects 400,000 people in England and Wales, striking three times more women than men. It is most common between the ages of 40 and 70. Half of victims are unable to work through disability within ten years.
Professor Isaacs said it was vital to treat people as early as possible with the most effective drugs. He added: ‘We have evidence that if you can stop the disease early, you can change the way it progresses for the rest of the patient’s life.
‘This is particularly important when it strikes at a young age – women can be affected in their 40s and 50s but it can start in the 20s and younger.’
Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: ‘We are delighted with Nice’s decision, as there are so many patients with rheumatoid arthritis in need of tighter disease management.
‘This decision is most welcome as it is vital that patients have effective options available as soon as one treatment approach fails.’
Professor Carole Longson, director of the health technology evaluation centre at Nice, said: ‘Rheumatoid arthritis can have a huge impact on quality of life and for many it’s a disabling condition, so we’re pleased to recommend tocilizumab at an additional stage in treating the condition.’
The drug was also approved in December for children with systemic juvenile arthritis, a severe inflammatory disease that can affect those as young as 18 months.
Around 2,500 children in Britain are living with the disease, which can persist into adulthood and cause significant disability.